Is early antiviral therapy for recurrent hepatitis C after liver transplantation superior to later treatment? The answer is no
Bruno Roche, Didier Samuel – 31 March 2011
Microglia activation in hepatic encephalopathy in rats and humans
Irina Zemtsova, Boris Görg, Verena Keitel, Hans‐Jürgen Bidmon, Karsten Schrör, Dieter Häussinger – 30 March 2011 – Astrocytes play an important role in the pathogenesis of hepatic encephalopathy (HE) and ammonia toxicity, whereas little is known about microglia and neuroinflammation under these conditions. We therefore studied the effects of ammonia on rat microglia in vitro and in vivo and analyzed markers of neuroinflammation in post mortem brain tissue from patients with cirrhosis with and without HE and non‐cirrhotic controls.
Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells
Itziar Echeverria, Alexander Pereboev, Leyre Silva, Aintzane Zabaleta, José Ignacio Riezu‐Boj, Marta Bes, María Cubero, Francisco Borras‐Cuesta, Juan José Lasarte, Juan Ignacio Esteban, Jesús Prieto, Pablo Sarobe – 30 March 2011 – Injection of dendritic cells (DCs) presenting viral proteins constitutes a promising approach to stimulate T cell immunity against hepatitis C virus (HCV). Here we describe a strategy to enhance antigen loading and immunostimulatory functions of DCs useful in the preparation of therapeutic vaccines.
Diagnosis and management of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
Bruce R. Bacon, Paul C. Adams, Kris V. Kowdley, Lawrie W. Powell, Anthony S. Tavill – 30 March 2011
Outcome of patients suffering from a spontaneous reactivation of hepatitis B presenting as acute‐on‐chronic liver failure and treated with antivirals
Chia‐Yen Dai, Ming‐Lun Yeh, Chung‐Feng Huang, Jee‐Fu Huang, Ming‐Lung Yu, Wan‐Long Chuang – 30 March 2011
Histological diagnosis of early hepatocellular carcinoma
Morris Sherman – 30 March 2011
p19ARF/p14ARF controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma
Doris Schneller, Georg Machat, Alexandra Sousek, Verena Proell, Franziska van Zijl, Gudrun Zulehner, Heidemarie Huber, Markus Mair, Markus K. Muellner, Sebastian M.B. Nijman, Robert Eferl, Richard Moriggl, Wolfgang Mikulits – 30 March 2011 – Signal transducer and activator of transcription 3 (Stat3) is activated in a variety of malignancies, including hepatocellular carcinoma (HCC). Activation of Ras occurs frequently at advanced stages of HCC by aberrant signaling through growth factor receptors or inactivation of effectors negatively regulating Ras signaling.
Hepatitis C virus targets the T cell secretory machinery as a mechanism of immune evasion
Danijela Petrovic, Zania Stamataki, Eugene Dempsey, Lucy Golden‐Mason, Michael Freeley, Derek Doherty, David Prichard, Catherine Keogh, Jennifer Conroy, Siobhan Mitchell, Yuri Volkov, Jane A. McKeating, Cliona O'Farrelly, Dermot Kelleher, Aideen Long – 30 March 2011 – T cell activation and the resultant production of interleukin (IL‐2) is a central response of the adaptive immune system to pathogens, such as hepatitis C virus (HCV). HCV uses several mechanisms to evade both the innate and adaptive arms of the immune response.
Efforts at making the diagnosis of acute‐onset autoimmune hepatitis
Keiichi Fujiwara, Shin Yasui, Osamu Yokosuka – 30 March 2011
Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma
Gonzalo Sapisochin, Nicholas Fidelman, John P. Roberts, Francis Y. Yao – 24 March 2011 – Mixed hepatocellular cholangiocarcinoma (HCC‐CC) and intrahepatic cholangiocarcinoma (I‐CC) are increasingly being reported in patients with cirrhosis.